<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15</volume><submitter>Yuan J</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>With an aging population, knee arthroplasty is increasingly common; however, chronic postsurgical pain (CPSP) affects up to 30% of patients. This study aims to evaluate the efficacy of 5% lidocaine-medicated plaster (LP5) in preventing CPSP among patients undergoing knee arthroplasty.&lt;h4>Methods&lt;/h4>This is a dual-center, randomized, double-blind, placebo-controlled trial involving 128 adult patients scheduled for knee arthroplasty. Participants will be randomly assigned, stratified by center, to either the LP5 group or the placebo group (n = 64 per group). The LP5 or placebo group will apply the patch 1 day before surgery and on postoperative days 1-3, with multimodal analgesia administered postoperatively. Multimodal analgesia will include intraoperative flurbiprofen a</pubmed_abstract><journal>Frontiers in pharmacology</journal><pagination>1486217</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11540780</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Effect of 5% lidocaine-medicated plaster in preventing chronic postsurgical pain after knee replacement: protocol for a randomized double-blind placebo-controlled trial.</pubmed_title><pmcid>PMC11540780</pmcid><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Jin X</pubmed_authors><pubmed_authors>Guo J</pubmed_authors><pubmed_authors>Xu H</pubmed_authors><pubmed_authors>Yuan J</pubmed_authors><pubmed_authors>Yu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Effect of 5% lidocaine-medicated plaster in preventing chronic postsurgical pain after knee replacement: protocol for a randomized double-blind placebo-controlled trial.</name><description>&lt;h4>Background&lt;/h4>With an aging population, knee arthroplasty is increasingly common; however, chronic postsurgical pain (CPSP) affects up to 30% of patients. This study aims to evaluate the efficacy of 5% lidocaine-medicated plaster (LP5) in preventing CPSP among patients undergoing knee arthroplasty.&lt;h4>Methods&lt;/h4>This is a dual-center, randomized, double-blind, placebo-controlled trial involving 128 adult patients scheduled for knee arthroplasty. Participants will be randomly assigned, stratified by center, to either the LP5 group or the placebo group (n = 64 per group). The LP5 or placebo group will apply the patch 1 day before surgery and on postoperative days 1-3, with multimodal analgesia administered postoperatively. Multimodal analgesia will include intraoperative flurbiprofen a</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2026-07-16T19:55:01.525Z</modification><creation>2025-04-06T11:46:17.964Z</creation></dates><accession>S-EPMC11540780</accession><cross_references><pubmed>39512815</pubmed><doi>10.3389/fphar.2024.1486217</doi></cross_references></HashMap>